Showing results (1781-1790 of 1,881) with videos related to
Sort By:
Pageof 189
Immunotherapy|October 14, 2025
Allogeneic CAR-T cell therapy in autoimmune diseasesYuanyuan Ma, Juliang Qin, Mingyao Liu, et al.Immunotherapy|October 23, 2019
Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedemaJacqueline R Hwang, Gloria Hwang, Ansh Johri, et al.Immunotherapy|April 23, 2020
Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomavirusesHeidar Ali Panahi, Azam Bolhassani, Gholamreza Javadi, et al.Immunotherapy|April 24, 2020
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literatureOlga Nigro, Graziella Pinotti, Rossana Gueli, et al.Immunotherapy|April 21, 2020
Small-molecule-based immunotherapy for immunologically mediated skin conditionsAlvise Sernicola, Irene Russo, Mauro AlaibacImmunotherapy|April 21, 2020
Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitisPrachi Bhave, Alan Pham, Adam Gordon, et al.Immunotherapy|September 19, 2025
Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case reportFaraah Bekheet, Melanie Ashland, Rochelle Reyes, et al.Immunotherapy|May 10, 2021
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacyIlya Polishchuk, Alexander Yakobson, Melanie Zemel, et al.Immunotherapy|June 12, 2020
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancerSabrina Rossi, Luca Toschi, Giovanna Finocchiaro, et al.Immunotherapy|July 28, 2025
The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature reviewMaen Abdelrahim, Abdullah EsmailPageof 189